期刊文献+

艾滋病患者血清中miR-210-5p和miR-296-5p的表达及其与临床病理特征及预后的关系 被引量:1

Expression of miR-210-5p and miR-296-5p in serum of AIDS patients and their relationship with clinicopathological features and prognosis
下载PDF
导出
摘要 目的 探讨miR-296-5p、miR-210-5p在艾滋病(AIDS)患者血清中的表达及与临床病理特征及预后的关系。方法 选取2018年8月至2021年8月四川省泸州市人民医院收治的165例AIDS患者作为研究组,同时选取165例健康体检者作为对照组。检测miR-296-5p、miR-210-5p水平;评价miR-210-5p、miR-296-5p水平对AIDS患者预后不良的诊断价值;采用多因素Logistic回归风险模型分析AIDS患者的预后影响因素。结果 miR-210-5p在AIDS患者血清中的表达较对照组升高,miR-296-5p表达较对照组降低,二者表达呈负相关(r=-0.487,P<0.05);预后不良组患者miR-296-5p表达水平低于预后良好组,miR-210-5p水平高于预后良好组,差异具有统计学意义(P<0.05);AIDS患者血清中miR-210-5p、miR-296-5p表达与有无生殖器疱疹、有无淋巴瘤、人类免疫缺陷病毒(HIV)载量有关(P<0.05);受试者工作特征(ROC)曲线结果显示,血清miR-296-5p、miR-210-5p水平预测AIDS患者预后不良的曲线下面积(AUC)分别为0.911(95%CI:0.858~0.949)、0.780(95%CI:0.710~0.840),对应的灵敏度分别为94.87%、60.26%,特异度分别为78.26%、85.87%,二者联合预测的AUC为0.940(95%CI:0.892~0.970),灵敏度为89.74%,特异度为86.96%;Logistic回归分析结果显示,有无淋巴瘤、白蛋白、C反应蛋白、miR-210-5p、miR-296-5p均为AIDS患者预后的影响因素(P<0.05)。结论 AIDS患者血清中miR-296-5p呈低表达,miR-210-5p呈高表达,二者表达呈负相关,且与AIDS患者病情及预后关系密切。 Objective To investigate the expression of miR-296-5p and miR-210-5p in serum of acquired immune deficiency syndrome(AIDS) patients and their relationship with clinicopathological features and prognosis. Methods 165 AIDS patients admitted to Luzhou People′s Hospital from August 2018 to August 2021 were selected as the research group, and 165 healthy people were selected as the control group. The levels of miR-296-5p and miR-210-5p were detected. The diagnostic value of miR-210-5p and miR-296-5p levels in poor prognosis of AIDS patients was evaluated. Multivariate Logistic regression risk model was used to analyze the prognostic factors of AIDS patients. Results The expression of miR-210-5p in the serum of AIDS patients was higher than that of the control group, and the expression of miR-296-5p was lower than that of the control group, and the two expressions were negatively correlated(r=-0.487, P<0.05);the expression level of miR-296-5p in the poor prognosis group was lower than that in the good prognosis group, and the level of miR-210-5p was higher than that in the good prognosis group(P<0.05);the expressions of miR-210-5p and miR-296-5p in the serum of AIDS patients were related to the presence or absence of genital herpes, the presence or absence of lymphoma, and human immune deficiency virus(HIV) load(P<0.05). The receiver operating characteristic(ROC) curve results showed that the area under curve(AUC) of serum miR-296-5p and miR-210-5p levels in predicting poor prognosis in AIDS patients was 0.911(95%CI:0.858-0.949) and 0.780(95%CI:0.710-0.840), respectively, the sensitivity was 94.87% and 60.26%, and the specificity was 78.26% and 85.87%, respectively, The AUC predicted by the two combined was 0.940(95% CI:0.892-0.970), with a sensitivity of 89.74% and a specificity of 86.96%. Logistic regression analysis showed that lymphoma, albumin, C-reactive protein, miR-210-5p and miR-296-5p were all prognostic factors in AIDS patients(P<0.05). Conclusions The expression of miR-296-5p was low in the serum of AIDS patients, and miR-210-5p was high. The expressions of the two were negatively correlated, and were closely related to the disease condition and prognosis of AIDS patients.
作者 王利琴 徐春梅 黄永茂 WANG Liqin;XU Chunmei;HUANG Yongmao(AIDS Treatment and Management Office,Luzhou People′s Hospital,Luzhou 646000,Sichuan,China;The Second Department of Infection,Zhongshan Hospital,the Affiliated Hospital of Southwest Medical University,Luzhou 646000,Sichuan,China)
出处 《中国性科学》 2023年第2期144-148,共5页 Chinese Journal of Human Sexuality
关键词 艾滋病 miR-210-5p miR-296-5p 病理特征 预后 AIDS MiR-210-5p MiR-296-5p Pathological features Prognosis
  • 相关文献

参考文献13

二级参考文献105

  • 1苏琛,彭鑫,刘晶晶.培元胶囊联合HAART对艾滋病免疫重建不良的临床观察[J].中国艾滋病性病,2020,0(1):19-22. 被引量:13
  • 2宋春鸽,孙亮,田庆丰.某省部分县区艾滋病病人服药依从性现况调查及影响因素分析[J].河南医学研究,2006,15(2):163-168. 被引量:6
  • 3艾滋病诊疗指南[J].中国感染与化疗杂志,2006,6(4):265-279. 被引量:42
  • 4李金山,李艳丽,蒋士卿.中西医结合治疗AIDS合并肝损伤疗效观察[J].河南中医学院学报,2006,21(5):6-6. 被引量:4
  • 5WHO STATEMENT. Accelerate expansion of antiretroviral therapy to all people living with HIV: WHO [ DB/OL ]. ( 2015-11-30 ) [ 2015-12-10 ]. http://www, who. int/mediacentre/news/statements/ 2015/antiretroviral-therapy-hiv/en/.
  • 6FAUCI A S, MARSTON H D. Ending the HIV-AIDSpandemic-follow the science [ J ]. N Engl J Meal, 2015, 373(23) :2197-2199.
  • 7FRIEDEN T R, FOTI K E, MERMIN J. Applying public health principles to the HIV epidemic-how are we doing? [J]. N Engl J Meal, 2015, 373(23): 2281-2287.
  • 8Insight Start Study Group, LUNDGREN J D, BABIKER A G, et al. Initiation of antiretroviral therapy in early asymptomatie HIV infection [ J ]. N Engl J Med, 2015, 373(9):795-807.
  • 9COHEN C, WOHL D, ARRIBAS JR, et al. Week 48 results from a randomized clinical trial of rilpivirine/ emtrieitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-l-infected adults [ J ]. AIDS, 2014, 28 (7) :989-997.
  • 10COHEN C J, MOLINA J M, CASSETI3 I, et al. Week 96 efficacy and safety of rilpivirine in treatment- naive, HIV-1 patients in two Phase III randomized trials[J]. AIDS, 2013, 27(6) :939-950.

共引文献59

同被引文献9

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部